|[May 31, 2014]
Clovis Oncology's CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1/2 Study Results in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
CHICAGO --(Business Wire)--
Clovis Oncology (NASDAQ:CLVS) announced today updated findings from the
Phase 1 and early Phase 2 portions of its ongoing Phase 1/2 clinical
study of CO-1686, the Company's novel, oral, targeted covalent
(irreversible) inhibitor of mutant forms of the epidermal growth factor
receptor (EGFR) for the treatment of non-small cell lung cancer in
patients with initial activating EGFR mutations as well as the dominant
resistance mutation T790M. These data are being presented today in an
oral presentation by Dr. Lecia Sequist at the 2014 American Society of
Clinical Oncology (ASCO) annual meeting in Chicago.
"Currently, there are no approved treatments for EGFR patients with
acquired resistance to targeted therapy," said Lecia V. Sequist, MD,
MPH, Massachusetts General Hospital Cancer Center and Associate
Professor of Medicine at Harvard Medical School and the lead
investigator for the Phase 1/2 study of CO-1686. "This ever-growing
population of patients is in dire need of effective agents. The initial
experience with CO-1686 provides hope that we are finally entering an
era where we may be able to successfully target resistance to EGFR
"In the year since our first presentation of clinical data for CO-1686,
we have made great strides in the development of this drug," said
Patrick J. Mahaffy, President and CEO of Clovis Oncology. "We are
extremely pleased with the consistency of the efficacy demonstrated to
date, the growing evidence of a lengthy duration of benefit and that
CO-1686 is so well-tolerated with a manageable side effect profile.
Additionally, the receipt of Breakthrough Therapy Designation from FDA
earlier this month supports our commitment to file an NDA by mid-2015
and make this drug available to treating physicians and the patients
that may benefit as rapidly as possible."
The Phase 1 dose escalation portion of the study is being conducted in
the United States, France and Australia in patients with metastatic or
unresectable recurrent NSCLC and a documented EGFR mutation. Patients
were not required to be T790M positive for the Phase 1 portion of the
study but had to have progressed on prior EGFR-directed tyrosine kinase
inhibitor (TKI) therapy (prior chemotherapy was also allowed).
The two Phase 2 expansion cohorts are currently enrolling in the United
States, Europe, and Australia in EGFR mutant patients with the T790M
mutation. The first cohort includes approximately 150 to 200 T790M
positive patients directly after progression on their first and only TKI
therapy, comparable to the population planned for the TIGER2
registration study. The second cohort includes approximately 150 to 200
later-line T790M positive patients after progression on their second or
later TKI therapy or subsequent chemotherapy. Both cohorts are exploring
doses of 500mg, 625mg and 750mg BID.
Approximately 160 patients have been treated with CO-1686 to date across
all dosing cohorts in the trial. Data from 81 evaluable patients treated
with CO-1686 at efficacious doses (comprising patients treated with
900mg BID of freebase or any dose of the hydrobromide salt (HBr)
formulation) were presented today, including 72 from the Phase 1 study
and nine from the early part of the Phase 2 portion of the study. Of
these 81 patients, 40 are centrally-confirmed T790M positive.
Patients enrolled in the Phase 1 study were heavily pretreated prior to
receiving CO-1686; 75 percent of patients across all doses had
immediately progressed on TKI therapy prior to CO-1686 treatment. The
median number of previous lines of therapy across patients at all doses
was three; the median number of previous TKI lines was two.
Evidence of Activity
In the 40 evaluable centrally-confirmed T790M positive patients acros
efficacious dose levels in the Phase 1 dose-expansion study and the
early Phase 2 expansion cohorts, 23 partial responses (PRs) have been
observed to date, for a 58 percent objective response rate (ORR).
Thirty-six of the 40 evaluable T790M positive patients, or 90 percent,
have experienced stable disease or a PR. Central nervous system (CNS)
responses have also been observed in heavily pre-treated T790M positive
The median duration of response cannot yet be determined in the T790M
positive patients. Similarly, median PFS has not been reached. However,
follow-up for some patients exceeds one year, and the current estimate
for median PFS is greater than 12 months.
Safety and Tolerability
CO-1686 is well-tolerated, with no evidence of systemic wild-type EGFR
inhibition. In the Phase 1 study, the most common adverse events were
nausea, hyperglycemia, diarrhea, vomiting and decreased appetite, and
these were mostly grade 1 or 2 in severity. The most common grade 3
adverse event was hyperglycemia, which was observed in 22 percent of
patients. Hyperglycemia, when observed and requiring treatment, is
typically managed with a commonly-prescribed single oral agent.
The presentation, titled "First-in-human evaluation of CO-1686: An
irreversible, highly-selective tyrosine kinase inhibitor of mutations of
EGFR (activating and T790M)" was presented on Saturday, May 31, during
the Clinical Science Symposium session titled "Targeting EGFR: The Next
10 Years", from 8:00 to 9:30am Central Time. The presentation is
available at www.clovisoncology.com.
CO-1686 Clinical Development
The Company is currently enrolling two Phase 2 expansion cohorts of its
Phase 1/2 study in EGFR mutant patients with the T790M mutation; the
first includes approximately 150 to 200 T790M positive patients directly
after progression on their first and only TKI therapy, comparable to the
population the Company will seek to enroll in its TIGER2 registration
study. The second cohort includes approximately 150 to 200 later-line
T790M positive patients after progression on their second or later TKI
therapy or subsequent chemotherapy. Both cohorts are exploring doses of
500mg, 625mg and 750mg BID.
Data from the expansion cohorts, combined with data from TIGER2, are
expected to serve as the basis of an NDA submission for CO-1686 by
Clovis expects to initiate three registration studies in the TIGER
program during 2014. The TIGER2 study, in T790M positive patients
directly after progression on their first and only TKI therapy, is
expected to begin enrolling patients at a dose of 625mg BID during the
second quarter. The Phase 2 portion of the TIGER1 study, which is a
randomized Phase 2/3 registration study of CO-1686 vs. erlotinib in
newly-diagnosed EGFR mutant patients is expected to begin in mid-2014,
and the TIGER3 study, a randomized, comparative study versus
chemotherapy in T790M positive patients directly after progression on
their first and only TKI therapy, is expected to initiate during the
second half of 2014.
The Company initiated its Phase 1 study of CO-1686 in Japan during the
first quarter of 2014.
Event Webcast Details
Clovis will host an investor/analyst event at ASCO this evening from
5:30 to 6:30pm Central Time. The event will be simultaneously webcast on
the Company's web site at www.clovisoncology.com,
and archived for future review.
CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of
the cancer-causing mutant forms of epidermal growth factor receptor
(EGFR) currently being studied for the treatment of non-small cell lung
cancer (NSCLC). CO-1686 was designed to selectively target both the
initial activating EGFR mutations as well as the T790M resistance
mutation, while sparing wild-type, or "normal" EGFR. Accordingly, it has
the potential to treat NSCLC patients with EGFR mutations both as a
first-line or second-line treatment with a reduced toxicity profile
compared to current EGFR inhibitor therapies.
About EGFR and Lung Cancer
Lung cancer is the most common cancer worldwide with 1.7 million new
cases annually, with NSCLC accounting for almost 85 percent of all lung
cancers. NSCLC progresses rapidly with a five-year survival rate in
advanced NSCLC patients of less than five percent. EGFR activating
mutations occur in approximately 10 to 15 percent of NSCLC cases in
Caucasian patients and approximately 30 to 35 percent in East Asian
patients. These patients experience significant tumor response currently
approved EGFR inhibitors which are first-generation EGFR inhibitors.
However, most patients ultimately progress on these therapies, with
approximately 60 percent of patients developing acquired resistance from
a second, or "gatekeeper" mutation, T790M.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer agents
in the U.S., Europe and additional international markets. Clovis
Oncology targets development programs at specific subsets of cancer
populations, and simultaneously develops diagnostic tools that direct a
compound in development to the population that is most likely to benefit
from its use. Clovis Oncology is headquartered in Boulder, Colorado.
To the extent that statements contained in this press release are not
descriptions of historical facts regarding Clovis Oncology, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve substantial risks and uncertainties
that could cause our clinical development programs, future results,
performance or achievements to differ significantly from those expressed
or implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in our
clinical development programs for our drug candidates, the corresponding
development pathways of our companion diagnostics, actions by the FDA,
the EMA (News - Alert) or other regulatory authorities regarding whether to approve
drug applications that may be filed, as well as their decisions
regarding drug labeling, and other matters that could affect the
availability or commercial potential of our drug candidates or companion
diagnostics, including competitive developments. Clovis Oncology
does not undertake to update or revise any forward-looking statements. A
further description of risks and uncertainties can be found in Clovis
Oncology's filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its reports on Form 10-Q
and Form 8-K.
[ Back To Unified Communications 's Homepage ]